Prostate Cancer

Prostate Cancer ADT Linked to Higher Risk of Liver Diseases

Prostate Cancer ADT Linked to Higher Risk of Liver Diseases

By

Men who received androgen deprivation therapy for prostate cancer were 54% more likely to be diagnosed with non-alcoholic fatty liver disease than those who did not, a study found.

Prostate Cancer AS Loss to Follow-Up Risk at 2 Years Estimated at 10%

Prostate Cancer AS Loss to Follow-Up Risk at 2 Years Estimated at 10%

By

The risk being lost to follow-up while on active surveillance for prostate cancer is higher among blacks than whites, according to a study.

Prazosin May Lower Prostate Cancer Recurrence Risk After Radiotherapy

Prazosin May Lower Prostate Cancer Recurrence Risk After Radiotherapy

By

LUTS treatment with the alpha-blocker prazosin was associated with significantly lower 2- and 5-year biochemical recurrence rates vs tamsulosin and non-use of alpha-blockers.

Advances in Imaging, Therapies Bode Well for nmCRPC Management

Advances in Imaging, Therapies Bode Well for nmCRPC Management

By

Novel imaging and tumor biomarker assays are likely to define non-metastatic castration-resistant prostate cancer more accurately, authors of new review state.

LDR Brachytherapy Beneficial In High-Risk Prostate Cancer

LDR Brachytherapy Beneficial In High-Risk Prostate Cancer

By

Low-dose-rate brachytherapy is associated with excellent long-term biochemical control and survival, new study finds.

Prostate Cancer Risk Lower In Men in Physically Demanding Jobs

Prostate Cancer Risk Lower In Men in Physically Demanding Jobs

By

Even low cumulative exposure to physical strain at work is associated with a decreased risk of prostate cancer, study finds.

Prostate MRI Use Ups Odds of Prostate Cancer Observation

Prostate MRI Use Ups Odds of Prostate Cancer Observation

By

In a study, men with low-risk prostate cancer were nearly 2-fold more likely to be managed with observation if they had a prostate MRI during the diagnostic work-up.

Decline in Surgical Overtreatment of Prostate Cancer Reported

Decline in Surgical Overtreatment of Prostate Cancer Reported

By

At a major tertiary referral center, the use of radical prostatectomy for insignificant prostate cancer decreased from 15% in 2009 to 3% in 2016, a study found.

Prostate Cancer Diagnoses Increase Men's Suicide Risk

Prostate Cancer Diagnoses Increase Men's Suicide Risk

By

A patient's risk of suicide is doubled within the first year following a prostate cancer diagnosis, according to a new meta-analysis.

Obese Prostate Cancer Patients Do Worse After Radical Prostatectomy

Obese Prostate Cancer Patients Do Worse After Radical Prostatectomy

By

Study of Korean radical prostatectomy patients showed that those who were obese had significant increased odds of biochemical recurrence and cancer-specific mortality

Cytoreductive Surgery for Metastatic PCa Linked to More Complications

Cytoreductive Surgery for Metastatic PCa Linked to More Complications

By

Cytoreductive radical prostatectomy (RP) for metastatic prostate cancer (PCa) is associated with higher complication rates and longer hospital stays than RP for non-metastatic PCa.

The Potential Role for PARP Inhibitors in Prostate Cancer

The Potential Role for PARP Inhibitors in Prostate Cancer

Identification of DNA repair defects within prostate cancer tissue may enable a precision oncologic approach to treatment.

Persistent Cancer Screening Gaps Revealed in New CDC Report

Persistent Cancer Screening Gaps Revealed in New CDC Report

From 2000 to 2015 screening for breast, cervical, and prostate cancers decreased significantly, whereas screening for colorectal cancer increased significantly.

Use of Post-RP High Dose Radiotherapy Increasing

Use of Post-RP High Dose Radiotherapy Increasing

By

Physicians increasingly are prescribing high dose and very high dose radiation therapy after radical prostatectomy despite an absence of randomized trials supporting the practice.

First-Line Enzalutamide May Confer a Survival Benefit for mCRPC

First-Line Enzalutamide May Confer a Survival Benefit for mCRPC

Patients may benefit from earlier lines of enzalutamide for the treatment of metastatic castration-resistant prostate cancer.

SBRT Appears Effective for Oligometastatic Prostate Cancer

SBRT Appears Effective for Oligometastatic Prostate Cancer

By

Stereotactic body radiation therapy achieves good local control of metastases in patients with recurrent prostate cancer following primary treatment.

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

Prostate Cancer Brachytherapy Outcomes Linked to PSADT

By

Shorter PSA double times are associated with worse disease-specific, metastasis-free, and overall survival, study finds.

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

Prostate Cancer Outcomes Improve With Tailored Post-RP Treatment

By

Radiation therapy dose escalation, pelvic lymph node irradiation, and hormone therapy duration are prescribed based on patient and tumor characteristics.

Prostate Cancer Risk Reduced in Men with Very Low Free Testosterone

Prostate Cancer Risk Reduced in Men with Very Low Free Testosterone

By

Men in the bottom 10th of free testosterone level vs those with higher levels were found to have a 23% decreased risk of prostate cancer.

Study Supports Prostate Cancer Active Surveillance for Younger Men

Study Supports Prostate Cancer Active Surveillance for Younger Men

By

Younger men with prostate cancer are less likely to experience Gleason score upgrading and pathologic progression on repeat biopsy.

Salvage RARP Feasible, Effective

Salvage RARP Feasible, Effective

By

According to researchers, 57.3% of men who underwent salvage robot-assisted radical prostatectomy were pad-free at 12 months.

Shorter ADT Course May Suffice for High-Risk Prostate Cancer

Shorter ADT Course May Suffice for High-Risk Prostate Cancer

By

New study shows no significant difference in overall survival between 18 and 36 months of androgen deprivation therapy used in combination with radiation therapy.

Aggressive Therapy Warranted for Gleason 10 Prostate Cancer

Aggressive Therapy Warranted for Gleason 10 Prostate Cancer

By

Regardless of treatment modality, men with Gleason 10 prostate cancer have high 5-year overall survival rates, new study finds.

PET/CT May Improve Imaging of Recurrent Prostate Cancer

PET/CT May Improve Imaging of Recurrent Prostate Cancer

By

Early study results are encouraging, but high-quality data that validate PET/CT against a reliable reference standard are lacking.

Adding MRI Does Not Boost Prostate Cancer Upgrading Rate

Adding MRI Does Not Boost Prostate Cancer Upgrading Rate

By

MRI with targeted prostate biopsy plus systematic biopsy fails to improve detection of upgrading in men on active surveillance for prostate cancer vs systematic biopsy alone.

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

FDA Approves Enzalutamide for Nonmetastatic Castration-Resistant Prostate Cancer

This latest approval now makes enzalutamide the only FDA-approved oral medication indicated for both metastatic and nonmetastatic castration-resistant prostate cancer.

Prostate Cancer ADT Ups Thromboembolic Event Risk

Prostate Cancer ADT Ups Thromboembolic Event Risk

By

Pulmonary embolism is associated with GnRH agonist use and orchiectomy.

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa

Partial Brachytherapy May Lead to Poor Outcomes in Intermediate-Risk PCa

The impact of partial brachytherapy on metastasis and disease-specific mortality is unclear.

Advanced Prostate Cancer Variant More Common Than Thought

Advanced Prostate Cancer Variant More Common Than Thought

Incidence of tx-emergent small-cell neuroendocrine prostate cancer 17% among those with mCRPC.

Focal HIFU Effective Over 5 Years for PCa

Focal HIFU Effective Over 5 Years for PCa

By

Failure-free survival was 88% at 5 years among patients with nonmetastatic prostate cancer who underwent focal therapy with high-intensity focused ultrasound.

Renal and Urology News Articles

Sign Up for Free e-newsletters